Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 07, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ:ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THAT ON NOVEMBER 3, 2025 (THE GRANT DATE), ORIC GRANTED A TOTAL OF 18,400 NON-QUALIFIED STOCK OPTIONS AND 3,000 RESTRICTED STOCK UNITS TO ONE NEW NON-EXECUTIVE EMPLOYEE WHO BEGAN THEIR EMPLOYMENT WITH ORIC IN OCTOBER 2025.

ORIC PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 06, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THE PUBLICATION OF A PEER-REVIEWED RESEARCH PAPER IN CANCER RESEARCH, A JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.

ORIC PHARMACEUTICALS ANNOUNCES PUBLICATION IN CANCER RESEARCH ON THE DISCOVERY AND DEVELOPMENT OF ENOZERTINIB, A HIGHLY SELECTIVE, BRAIN-PENETRANT EGFR INHIBITOR

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, NOV. 04, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THAT MANAGEMENT WILL BE PARTICIPATING IN THE FOLLOWING INVESTOR CONFERENCES IN NOVEMBER:

ORIC PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, OCT. 27, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, PRESENTED POSTERS AT THE 2025 EORTC-NCI-AACR INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS HIGHLIGHTING PRECLINICAL DATA THAT FURTHER ILLUSTRATE THE POTENTIAL FOR ORIC-944, A POTENT AND SELECTIVE ALLOSTERIC INHIBITOR OF THE POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) VIA THE EMBRYONIC ECTODERM DEVELOPMENT (EED) SUBUNIT, TO TREAT PROSTATE CANCER AND VARIOUS OTHER SOLID TUMORS.

ORIC PHARMACEUTICALS PRESENTED PRECLINICAL DATA AT THE EORTC-NCI-AACR INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS SUPPORTING BEST-IN-CLASS POTENTIAL OF ORIC-944 TO TREAT PATIENTS WITH PROSTATE CANCER AND OTHER SOLID TUMORS

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, SEPT. 05, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ:ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THAT ON SEPTEMBER 2, 2025 (THE GRANT DATE), ORIC GRANTED A TOTAL OF 292,500 NON-QUALIFIED STOCK OPTIONS AND 79,000 RESTRICTED STOCK UNITS TO ONE NEW NON-EXECUTIVE OFFICER EMPLOYEE WHO BEGAN THEIR EMPLOYMENT WITH ORIC IN AUGUST 2025.

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, AUG. 27, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THAT MANAGEMENT WILL BE PARTICIPATING IN THE FOLLOWING INVESTOR CONFERENCES IN SEPTEMBER:

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, AUG. 18, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THE APPOINTMENT OF KEVIN BRODBECK, PHD, TO THE NEWLY ESTABLISHED ROLE OF CHIEF TECHNICAL OFFICER (CTO). DR. BRODBECK BRINGS MORE THAN 25 YEARS OF EXPERIENCE LEADING TECHNICAL OPERATIONS, QUALITY ASSURANCE, CHEMISTRY, MANUFACTURING AND CONTROLS (CMC), AND REGULATORY ACTIVITIES ACROSS A WIDE RANGE OF PHARMACEUTICAL PRODUCTS AT ALL STAGES OF DEVELOPMENT AND COMMERCIALIZATION. THE CREATION OF THE CTO ROLE AND DR. BRODBECK'S APPOINTMENT REFLECT THE IMPENDING ADVANCEMENT OF ORIC'S CLINICAL PROGRAMS INTO LATE-STAGE DEVELOPMENT WITH THE POTENTIAL START OF PHASE 3 TRIALS FOR ORIC-944 AND ENOZERTINIB (ORIC-114) IN 2026.

ORIC PHARMACEUTICALS EXPANDS LEADERSHIP TEAM WITH THE APPOINTMENT OF KEVIN BRODBECK AS CHIEF TECHNICAL OFFICER

REPORTED POTENTIALLY BEST-IN-CLASS CLINICAL EFFICACY AND SAFETY DATA FROM ONGOING PHASE 1B TRIAL OF ORIC-944 IN COMBINATION WITH AR INHIBITORS FOR THE TREATMENT OF PATIENTS WITH MCRPC STRENGTHENED CASH POSITION WITH $244 MILLION GROSS PROCEEDS FROM TOP-TIER HEALTHCARE SPECIALIST INVESTORS ACROSS $125 MILLION PRIVATE PLACEMENT FINANCING AND $119 MILLION ATM ISSUANCES; FOLLOWING RECENT FINANCING ACTIVITY, ORIC CONCLUDES ANTICIPATED ATM FACILITY USAGE IN ANTICIPATION OF POTENTIAL INITIATION OF REGISTRATIONAL TRIALS IN 2026 FOR ORIC-944 AND ORIC-114 (ENOZERTINIB), THE COMPANY HAS REVISED ITS OPERATING PLAN TO SUBSTANTIALLY REDUCE INVESTMENT IN DISCOVERY RESEARCH UNDER THE REVISED OPERATING PLAN AND WITH THE ADDITIONAL FINANCING, CASH AND INVESTMENTS EXPECTED TO PROVIDE RUNWAY INTO 2H 2028 (PREVIOUSLY 2H 2027) AND BEYOND ANTICIPATED PRIMARY ENDPOINT READOUTS FROM FIRST PHASE 3 TRIALS FOR ORIC-944 AND ORIC-114 (ENOZERTINIB) SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, AUG. 12, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY REPORTED FINANCIAL RESULTS AND OPERATIONAL UPDATES FOR THE QUARTER ENDED JUNE 30, 2025.

ORIC PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL UPDATES

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, AUG. 01, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ:ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THAT ON AUGUST 1, 2025 (THE GRANT DATE), ORIC GRANTED A TOTAL OF 35,000 NON-QUALIFIED STOCK OPTIONS AND 5,800 RESTRICTED STOCK UNITS TO TWO NEW NON-EXECUTIVE EMPLOYEES WHO BEGAN THEIR EMPLOYMENT WITH ORIC IN JULY 2025.

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, JULY 03, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ:ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THAT ON JULY 1, 2025 (THE GRANT DATE), ORIC GRANTED A TOTAL OF 9,000 NON-QUALIFIED STOCK OPTIONS AND 1,600 RESTRICTED STOCK UNITS TO ONE NEW NON-EXECUTIVE EMPLOYEE WHO BEGAN THEIR EMPLOYMENT WITH ORIC IN JUNE 2025.

SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, JUNE 06, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ:ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED THAT ON JUNE 2, 2025 (THE GRANT DATE), ORIC GRANTED A TOTAL OF 39,100 NON-QUALIFIED STOCK OPTIONS AND 6,500 RESTRICTED STOCK UNITS TO THREE NEW NON-EXECUTIVE EMPLOYEES WHO BEGAN THEIR EMPLOYMENT WITH ORIC IN MAY 2025.

FINANCING LED BY SR ONE AND INCLUDES PARTICIPATION FROM NEW AND EXISTING INVESTORS, INCLUDING POINT72, VIKING GLOBAL INVESTORS, VENROCK HEALTHCARE CAPITAL PARTNERS, NEW ENTERPRISE ASSOCIATES (NEA), NEXTECH, VIVO CAPITAL, AND NEXTBIO CAPITAL

ORIC PHARMACEUTICALS ANNOUNCES $125 MILLION PRIVATE PLACEMENT FINANCING

BROAD AND DEEP PSA RESPONSES ACHIEVED, WITH 59% PSA50 RESPONSE RATE (CONFIRMED RATE OF 47%, AND ONE ADDITIONAL RESPONSE PENDING CONFIRMATION) AND 24% PSA90 RESPONSE RATE (ALL CONFIRMED) IN PATIENTS WITH MCRPC   PSA RESPONSES WERE OBSERVED ACROSS ALL ORIC-944 DOSE LEVELS AND AT COMPARABLE RATES IN COMBINATION WITH APALUTAMIDE AND WITH DAROLUTAMIDE; MAJORITY OF PATIENTS ARE STILL ONGOING WITH MULTIPLE PATIENTS APPROACHING ONE YEAR OR MORE BOTH COMBINATION REGIMENS DEMONSTRATED A SAFETY PROFILE COMPATIBLE WITH LONG TERM DOSING, WITH THE VAST MAJORITY OF ADVERSE EVENTS GRADE 1 OR 2 ANNOUNCED CONCURRENT $125 MILLION FINANCING, WHICH EXTENDS CASH RUNWAY INTO 2H 2027 AND THROUGH ANTICIPATED PRIMARY ENDPOINT READOUT FROM FIRST PHASE 3 TRIAL SOUTH SAN FRANCISCO, CALIF. AND SAN DIEGO, MAY 28, 2025 (GLOBE NEWSWIRE) -- ORIC PHARMACEUTICALS, INC. (NASDAQ: ORIC), A CLINICAL STAGE ONCOLOGY COMPANY FOCUSED ON DEVELOPING TREATMENTS THAT ADDRESS MECHANISMS OF THERAPEUTIC RESISTANCE, TODAY ANNOUNCED POTENTIALLY BEST-IN-CLASS PRELIMINARY EFFICACY AND SAFETY DATA FROM THE ONGOING PHASE 1B TRIAL OF ONCE DAILY ORIC-944 IN COMBINATION WITH ANDROGEN RECEPTOR (AR) INHIBITORS IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).

ORIC PHARMACEUTICALS ANNOUNCES POTENTIALLY BEST-IN-CLASS PRELIMINARY EFFICACY AND SAFETY DATA FROM ONGOING PHASE 1B TRIAL OF ORIC-944 IN COMBINATION WITH AR INHIBITORS FOR THE TREATMENT OF PATIENTS WITH MCRPC

ORIC Pharmaceuticals, Inc.

ORIC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ORIC Pharmaceuticals, Inc.

ORIC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ORIC